NASDAQ · Biotechnology · USD

Seaport Therapeutics, Inc. (SPTX) Stock Analysis

Seaport Therapeutics, Inc. (SPTX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

SPTX

$24.86

+$0.57 (+2.35%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare SPTX with… →

SPTX Key Statistics

As of Sep 4, 2026

Trading

Open: $24.03
Previous Close: $24.29
Day's Range: 23.63–25.00
52-Week Range: 14.85–28.38
Volume: 104.30K

Valuation

Market Cap: $1.33B
P/E Ratio: unprofitable
EPS (ttm): −2.52

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$74.88M
Profit margin: 0.00%
Shares Outstanding: 53.53M

Dividend and dates

Avg Volume: 162.87K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

SPTX Revenue and Earnings by Fiscal Year

FY ends December

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$74.88M	—
2024	$0.00	−$46.88M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$87.29M	−$74.88M	—
2024	$0.00	—	−$52.42M	−$46.88M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

SPTX Valuation vs Biotechnology Median

Median of 656 stocks

Metric	SPTX	Biotechnology median	vs median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Seaport Therapeutics, Inc. (SPTX) is capitalised at $1.33B on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 58.

SPTX last closed at $24.86 on September 4, 2026. That is +$0.57 (+2.35%) against the previous close. Over the past 52 weeks the price has ranged from $14.85 to $28.38. The latest close sits 67.41% above that 52-week low.

Financial Health

In fiscal 2025, Seaport Therapeutics, Inc. reported revenue of $0.00. The same year closed with a net loss of $74.88M. Profit margin runs at 0%. Trailing earnings per share are −2.52.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Growth & Income

No dividend is on file for SPTX.

2026 is still running; the price is +25.30% year to date.

Peer Comparison

Seaport Therapeutics, Inc. (SPTX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Seaport Therapeutics, Inc.	SPTX	$1.33B	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Seaport Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Seaport Therapeutics, Inc.

Seaport Therapeutics, Inc., a clinical-stage therapeutics company, focuses on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. It is leveraging its proprietary Glyph platform to advance a pipeline of therapies to address the unmet needs in depression and anxiety. The company's lead product candidate, GlyphAllo (SPT-300 or Glyph Allopregnanolone), is a novel, Glyphed oral prodrug of allopregnanolone, an endogenous molecule that has been clinically validated in third-party trials for the treatment of postpartum depression. Its second product candidate, GlyphAgo (SPT-320 or Glyph Agomelatine), is a novel, Glyphed oral prodrug of agomelatine, a clinically validated anxiolytic and antidepressant that is approved for the treatment of generalized anxiety disorder in Australia and major depressive disorder in Australia and the European Union. The company was founded in 2024 and is based in Boston, Massachusetts.

Visit website →